Back

Intravenous antiplatelets: cangrelor is ready for prime time - PRO.

3 March 2018 (11:45 - 12:00)
Organised by:
Congress Presentation Part of: Great Debate on STEMI: current controversies on immediate treatment. Acute Coronary Syndromes: Antiplatelet Agents Open Access Acute Cardiovascular Care 2018

About the speaker

Photo
Associate Professor Sergio Leonardi

University of Pavia, Pavia (Italy)

9 More presentations in this session

Presentation thumbnail
PCI of non-IRA lesions immediately after primary PCI - PRO.(VIA ZOOM)
Professor K. Oldroyd (Glasgow, GB)
Slides Video
Presentation thumbnail
PCI of non-IRA lesions immediately after primary PCI - CONTRA.
Professor H. Thiele (Leipzig, DE)
Slides Video
Presentation thumbnail
PCI of non-IRA lesions immediately after primary PCI - Rebuttal PRO..(VIA ZOOM)
Professor K. Oldroyd (Glasgow, GB)
Video
Presentation thumbnail
PCI of non-IRA lesions immediately after primary PCI - Rebuttal CONTRA.
Professor H. Thiele (Leipzig, DE)
Slides Video
Presentation thumbnail
PCI of non-IRA lesions immediately after primary PCI: chairpersons conclusion.

Access the full session

Session thumbnail
Great Debate on STEMI: current controversies on immediate treatment.

The Event

Event poster

Acute Cardiovascular Care 2018

3 March 2018 11:45 CET
You may be interested in
thumbnail
Congress Presentation
Intravenous antiplatelet therapy with cangrelor vs. tirofiban in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
27 August 2022
thumbnail
Congress Presentation
Anti-thrombotic management in patients with acute coronary syndromes - discussion.
18 March 2022
thumbnail
Congress Presentation
Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients
1 September 2019
thumbnail
Congress Presentation
Evaluating cangrelor safety in extracorporeal cardiopulmonary resuscitation (E-CPR)
14 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources